Latest News

Filters

Filter by tags: Iodine-131 United States Clear all tag filters

10 news articles found

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Source: Nucnet
Date: Friday, 14 April 2023
Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023

The University of Missouri has launched an initiative to build a new, larger research reactor, NextGen MURR. The university's existing MU Research Reactor (MURR) - in operation for more than half a century - is the highest-powered university research reactor in the USA and is currently the country's only producer of certain medical radioisotopes.

Source: World Nuclear News
Date: Saturday, 01 April 2023
Original article: world-nuclear-news.org/Articles/New-isotope-producing-research-reactor-for-Missour

Belgium’s Institute for Radioelements (IRE), a key producer of molybdenum-99 (Mo-99) and iodine-131 (I-131) widely used in nuclear medicine, has complete conversion of its production process to low-enriched uranium (LEU). This has ended the use of highly enriched uranium (HEU), which is seen as a proliferation risk.

Source: NEI Magazine
Date: Friday, 31 March 2023
Original article: neimagazine.com/news/newsbelgiums-ire-moves-to-100-low-enriched-uranium-10719323

All major global molybdenum-99 (Mo-99) production facilities are now using low-enriched uranium (LEU) targets instead of proliferation-sensitive highly-enriched uranium (HEU) following the completion of work to convert Belgium's National Institute of Radioelements (IRE) medical isotope production facility.

Source: World Nuclear News
Date: Friday, 31 March 2023
Original article: world-nuclear-news.org/Articles/Mo-99-production-reaches-non-proliferation-milesto

SHINE Technologies of the USA has announced its European subsidiary, SHINE Europe, has secured funding to begin designing an advanced medical isotope production facility at Veendam in the Netherlands.

Source: World Nuclear News
Date: Thursday, 03 February 2022
Original article: world-nuclear-news.org/Articles/Financing-in-place-for-European-SHINE-isotope-plan

Of the 220 research reactors in operation today, only seven are on the African continent. In other words, with 17.2% of the world population and the strongest expected growth in the coming years, Africans have access to only 3% of the world's nuclear research reactor capacity. Marguerite Leonardi, senior advisor at NPC Consulting & Engineering, and Professor Vincent Lukanda Mwamba, Commissaire Général of the Commissariat Général à l’Energie Atomique, explain why that is a concern and why the research reactor in Kinshasa should be restarted urgently.

Source: World Nuclear News
Date: Tuesday, 13 October 2020
Original article: world-nuclear-news.org/Articles/Viewpoint-Why-research-reactors-are-so-important-f

Belgium’s Institute for Radioelements (IRE) has produced its first commercial molybdenum-99 (Mo-99) low enriched uranium (LEU) batch for the US market.

Source: NEI Magazine
Date: Friday, 08 May 2020
Original article: neimagazine.com/news/newsbelgium-produces-mo-99-for-the-usa-using-leu-fuel-7911908

Belgium's Institute of Radioelements (IRE) has produced its first batch of the medical radioisotope molybdenum-99 (Mo-99) using a low-enriched uranium (LEU) target rather than a high-enriched uranium (HEU) one. The use of HEU is seen as a potential nuclear proliferation risk.

Source: World Nuclear News
Date: Tuesday, 05 May 2020
Original article: world-nuclear-news.org/Articles/Belgium-starts-producing-Mo-99-using-LEU

December saw Russia sign various nuclear agreements with Uzbekistan, Brazil and Sudan as well as strengthening is co-operation with the Philippines.   

Source: NEI Magazine
Date: Thursday, 04 January 2018
Original article: neimagazine.com/news/newsrussia-signs-more-nuclear-cooperation-agreements-6018760

At unit 2, water with surface radiation of greater than 1000 mSv/hr was found leaking into the sea on April 2.

Reactor-by-reactor, system-by-system summary from JAIF on 4 April. Yellow indicates abnormal/unstable; red means damaged/nonfunctional/unsafe

Source: NEI Magazine
Date: Monday, 04 April 2011
Original article: neimagazine.com/news/newsleak-into-sea-found-at-fukushima-daiichi-site-721